Neuropsychological and Behavioral Testing in Young Patients With Cancer
Trial Purpose and Description
This clinical trial is studying neuropsychological and behavioral testing in young patients with cancer. Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function in young patients with cancer.
I. To utilize a standardized battery of age-appropriate neuropsychological and behavioral tests in conjunction with Children's Oncology Group (COG) Phase III clinical trials to evaluate cognitive, social, emotional, and behavioral functioning over time.
II. To institute procedures to ensure a consistent, streamlined, and efficient administration of the neuropsychological/behavioral tests in a cooperative group setting in order to maximize compliance with a standardized assessment battery conducted at 3 standardized timepoints.
Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery testing at 9, 30, and 60 months post-diagnosis in a 1-hour session conducted by a neuropsychologist or psychologist. The Battery consists of tests of intelligence, processing speed/attention, memory, language preference, general developmental progress, attention and behavior/social/emotional function, executive function, adoptive function, and quality of life. Additionally, parents complete a parent-report questionnaire to gather information about patient's function in terms of attention, memory, executive abilities, and behavioral, social, and emotional adaption.
- 1 Month - 21 Years
- Diagnosis of cancer
- Must be currently enrolled on a COG therapeutic study that aims to examine
neuropsychological, social, emotional, and/or behavioral functioning
- Must have receptive and expressive English language skills
- Patients with a history of severe or profound mental retardation (i.e. intelligence
quotient [IQ] =< 50) are not eligible for enrollment
- Children with a prior history of attention deficit hyperactivity disorder (ADHD)
or a specific learning disability (e.g. dyslexia) are eligible for this study
- All patients and/or their parents or legal guardians must sign a written informed
- Children's Oncology Group
- National Cancer Institute (NCI)
- September 2008
- Last Updated:
- June 11, 2013
- Study HIC#:
Clinicaltrials.gov ID: NCT00772200